论文部分内容阅读
为评价凯扶兰~(双氯酚酸钾)用于早孕负压吸宫术镇痛的疗效和可接受性,将405例受试对象根据既往分娩情况分为阴道分娩组和非阴道分娩组,再分别随机分为术前服用凯扶兰~50mg的观察组和 Vc 200mg 的对照组。按疼痛临床分级(0～4级)标准记录医生及受试者本人对扩张宫颈和负压吸宫过程中的疼痛分级,并记录药物的副反应及可接受性。结果显示,非阴道分娩组中:①轻度以下疼痛者观察组(46.6%)多于对照组(15.7%),(P<0.001);②认为疼痛易于耐受者观察组(60.2%)多于对照组(32.7%),(P<0.001);③医生和受试者认为服用凯扶兰~有效者分别为82.5%和84.5%,明显高于对照组49.5%和46.1%,(P<0.001);④仅8.7%凯扶兰~服用者表示不愿再用同种药物止痛,显著低于对照组的21.6%,(P<0.001)。阴道分娩组中观察组与对照组在上述方面无显著差异。结果提示,凯扶兰用于早孕负压吸宫术的镇痛,对无阴道分娩史,宫颈条件较差的妇女,效果尤为明显,加之其服药方便,副作用小,价格合理,有较好的临床推广前景。
To evaluate the efficacy and acceptability of trifurcate acephate (potassium diclofenac potassium) for pain relief in early pregnancy, the 405 subjects were divided into vaginal delivery group and non-vaginal delivery group Group, and then were randomly divided into preoperative taking clovene ~ 50mg observation group and Vc 200mg control group. According to the clinical grades of pain (Grade 0 ~ 4), the doctors and their subjects recorded the pain grade of the cervix and vacuum aspiration, and recorded the side effects and acceptability of the drug. The results showed that in the non-vaginal delivery group: (1) more pain in the observation group (46.6%) than in the control group (15.7%), (P <0.001); (32.7%) in the control group (P <0.001). ③The doctors and subjects thought that the effective dose of the effective dose of trifurine was 82.5% and 84.5% respectively, significantly higher than that of the control group (49.5% and 46.1%, P < 0.001). ④ Only 8.7% of the patients with clovene-blue showed that they did not want to use the same drugs to relieve pain again, which was significantly lower than that of the control group (21.6%, P <0.001). There was no significant difference between the observation group and the control group in vaginal delivery group. The results suggest that, for the first trimester vaginal abortion Miu Miu pain relief for non-vaginal delivery history, poor cervical conditions in women, the effect is particularly evident, coupled with its convenient medication, side effects, the price is reasonable, there is better Clinical promotion prospects.